National Institute of Allergy and Infectious Diseases (NIAID): Influenza, Human trials

The registry lists 186 Influenza, Human studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 11 are open to participants now and 54 have results posted.

Phase 1 96Phase 2 70Phase 3 5Phase 4 11No phase 23(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• H5N1 Vaccination With and Without AS03: Systems Biology AnalysisCompletedNCT01573312Phase 1
• Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy AdultsCompletedNCT01534468Phase 1
• Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV AloneCompletedNCT01498718Phase 1
• Experimental AD4-H5-VTN Vaccine in Healthy VolunteersCompletedNCT01443936Phase 1
• Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza VaccineCompletedNCT01443663Phase 1
• H5N1 Mix and Match With AS03CompletedNCT01317758Phase 1
• H5N1 Mix and Match With MF59CompletedNCT01317745Phase 1
• Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.CompletedNCT01262079
• Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 InfluenzaCompletedNCT01175122Phase 1
• Influenza Antiviral DAS181-F03CompletedNCT01173224Phase 1
• Comparison of Flu Vaccine Doses in ChildrenCompletedNCT01164553Phase 1
• Blood and Plasma Collection For Use in Future Clinical TrialsCompletedNCT01136057
• An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...CompletedNCT01086657Phase 1
• Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 VaccinesCompletedNCT01086566Phase 1
• Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With InfluenzaWithdrawnNCT01063933Phase 1/2
• Safety and Efficacy of Oseltamivir in Children Younger Than One Year of AgeWithdrawnNCT01037634Phase 2
• VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 YearsCompletedNCT00995982Phase 1
• A Pilot Study for Collection of Anti-Influenza A Immune PlasmaCompletedNCT00984451
• VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years OldCompletedNCT00973895Phase 1
• CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly PopulationsWithdrawnNCT00964951Phase 2
• Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7CompletedNCT00922259Phase 1
• Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59CompletedNCT00912496Phase 1
• Nontypeable H. Influenzae in Healthy AdultsCompletedNCT00905385Phase 1/2
• VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...CompletedNCT00858611Phase 1
• Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy AdultsCompletedNCT00853255Phase 1
• Vaccine for Prevention of Bird FluCompletedNCT00776711Phase 1
• High Dose Influenza in Immunosuppressed SubjectsWithdrawnNCT00766285Phase 2
• Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine VaccineCompletedNCT00734175Phase 1
• Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus VaccineCompletedNCT00722774Phase 1
• H5N1 (Clade 2) Vaccination of Adults and ElderlyCompletedNCT00680069Phase 1/2
• H9 Priming Study in Healthy AdultsCompletedNCT00617331Phase 2
• Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy AdultsCompletedNCT00546585Phase 1/2
• Influenza in People With Normal and Weakened Immune SystemsCompletedNCT00533182
• Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy AdultsCompletedNCT00516035Phase 1
• Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given IntradermallyCompletedNCT00489931Phase 1
• Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy AdultsCompletedNCT00488046Phase 1
• Clinical IGSP-CHOP BostonCompletedNCT00428831
• China Case Control Avian InfluenzaCompletedNCT00428753
• Prospective Study of AI H5N1 in ChinaCompletedNCT00428493
• Pilot Study of Genotypic AnalysisCompletedNCT00421837
• Inpatient Influenza SurveillanceCompletedNCT00419861
• Safety Study of Avian Flu VaccineCompletedNCT00408109Phase 1
• Th1 Response to Influenza: Aging and Vaccine EfficacyTerminatedNCT00396305Phase 4
• Proteomic Profiling for Influenza Vaccination - FluMistCompletedNCT00385281Phase 4
• Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in AdultsCompletedNCT00382980Phase 1
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)CompletedNCT00380237Phase 1
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy AdultsCompletedNCT00347672Phase 1
• T and B Cell Response to Avian Flu VaccineCompletedNCT00337896
• Pharma-Pen (Formerly Innoject) Auto-injectory TIVWithdrawnNCT00335855Phase 1
• Alternative Oseltamivir Dosing StrategiesCompletedNCT00334529Phase 2
• Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in AdultsCompletedNCT00333398Phase 3
• Cell-Mediated Immune Responses to Influenza A/H5N1 VaccineCompletedNCT00311727Not applicable
• Chart Review of Antivirals for Influenza in InfantsCompletedNCT00311701
• St. Jude Open Label H5 TrialCompletedNCT00311675Phase 1/2
• Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing FacilitiesCompletedNCT00311649Phase 1/2
• H5N1 Vaccine Intramuscular Versus Intradermal in Healthy AdultsCompletedNCT00310206Phase 1
• Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell LymphomaCompletedNCT00307177Phase 2
• Safety and Dose Study of Peramivir for Influenza TreatmentCompletedNCT00297050Phase 1
• H5 Vaccine Alone or With Adjuvant in Healthy AdultsCompletedNCT00296634Phase 1/2
• H5 Vaccine Alone or With Aluminum Hydroxide in Elderly AdultsCompletedNCT00294099Phase 1/2
• H5 Adult - Chiron Study of Bird Flu VaccineCompletedNCT00280033Phase 1/2
• Immunogenicity and Safety of Different Doses of Fluzone® InfluenzaCompletedNCT00253734Phase 2
• H5 Booster After a Two Dose ScheduleCompletedNCT00240968Phase 2
• Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) VaccineCompletedNCT00240903Phase 1
• Inactivated Influenza Vaccine in Infants 10-22 Weeks of AgeCompletedNCT00231920Phase 1
• A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and FlumistCompletedNCT00231907Phase 1
• Inactivated Influenza A/H5N1 Vaccine in the ElderlyCompletedNCT00230750Phase 1/2
• Comparison of Delivery Routes of Flu Vaccine in AdultsCompletedNCT00170547Phase 2
• Young Adult Influenza Vaccine Immunogenicity SubstudyCompletedNCT00170508Not applicable
• Elderly Influenza Vaccine Immunogenicity SubstudyCompletedNCT00170482
• Trivalent rHA Dose Escalation Study in Elderly SubjectsCompletedNCT00170443Phase 2
• T-cell Response-Flu Risk in Older AdultsCompletedNCT00138398Not applicable
• Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 AmendmentCompletedNCT00138385Phase 4
• Influenza Immunity Against Pandemic Respiratory VirusCompletedNCT00138281Phase 4
• Proteomic Profiling for InfluenzaCompletedNCT00133588Phase 4
• A/H5N1 Vaccine in Healthy Children Aged 2-9 YearsCompletedNCT00133536Phase 1/2
• FLU-VACS Comparative Study in AdultsCompletedNCT00133523Phase 4
• Influenza Vaccine in Pediatric Transplant SubjectsCompletedNCT00133510Phase 4
• Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory AdultsCompletedNCT00133471Phase 1/2
• A/H5N1in Adult - AventisCompletedNCT00115986Phase 1/2
• Eldery High Dose TIV 2005CompletedNCT00115531Phase 2
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)CompletedNCT00110279Phase 1
• Fluarix Immunogenicity and Safety TrialCompletedNCT00100399Phase 3
• Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and AdolescentsCompletedNCT00091702Phase 1/2
• Half-Dose Flu Vaccine Study in Healthy AdultsCompletedNCT00006146Phase 2
• Study of a Flu Vaccine in ChildrenCompletedNCT00001127Phase 3